# US 2004/0110817 A1 · Dipeptidyl peptidase IV inhibiting fluorinated cyclic amides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0110817 A1
- Document ID: US20040110817A1
- Status: Published application
- Kind: A1
- Application number: 10/713,299
- Filed: 2003-11-13
- Published: 2004-06-10
- Earliest claimed: 2002-11-18
- Assignees: Pfizer Inc.
- Inventors: Bernard Hulin
- Web page: https://patentgrep.com/patent/US20040110817A1

## CPC

- C07D 207/22: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/50: for increasing or potentiating the activity of insulin
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/10: for osteoporosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/32: Alcohol-abuse
- A61P 27/02: Ophthalmic agents
- A61P 27/12: for cataracts
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.

## Claims

### Claim 1

(2S)-2-Amino-2-cyclohexyl-1-((3RS)-3-fluoro-pyrrolidin-1-yl)-ethanone or (S)-2-amino-2-cyclohexyl-1-(3,3-difluoro-pyrrolidin-1-yl)-ethanone, or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

### Claim 3 (depends on 1)

A pharmaceutical composition comprising
a) a first compound comprising a compound of claim 1, or a pharmaceutically acceptable salt of said first compound; and
b) a second compound comprising insulin or an insulin analog; insulinotropin; a biguanide; an α-2 antagonist or imidazoline; a glitazone; an aldose reductase inhibitor; a glycogen phosphorylase inhibitor; a sorbitol dehydrogenase inhibitor; a fatty acid oxidation inhibitor; an α-glucosidase inhibitor; a β-agonist; a phosphodiesterase inhibitor; a lipid-lowering agent; an antiobesity agent; a vanadate, vanadium complex or peroxovanadium complex; an amylin antagonist; a glucagon antagonist; a growth hormone secretagogue; a gluconeogenesis inhibitor; a somatostatin analog; an inhibitor of renal glucose; an antilipolytic agent; or a pharmaceutically acceptable salt of said second compound.

### Claim 4 (depends on 3)

A pharmaceutical composition of claim 3 further comprising a pharmaceutically acceptable carrier or diluent.

### Claim 5 (depends on 1)

A kit comprising:
a) a first dosage form comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof;
b) a second dosage form comprising insulin or an insulin analog; insulinotropin; a biguanide; an α-2 antagonist or imidazoline; a glitazone; an aldose reductase inhibitor; a glycogen phosphorylase inhibitor; a sorbitol dehydrogenase inhibitor; a fatty acid oxidation inhibitor; an α-glucosidase inhibitor; a β-agonist; a phosphodiesterase inhibitor; a lipid-lowering agent; an antiobesity agent; a vanadate, vanadium complex or peroxovanadium complex; an amylin antagonist; a glucagon antagonist; a growth hormone secretagogue; a gluconeogenesis inhibitor; a somatostatin analog; an inhibitor of renal glucose; an antilipolytic agent; or a pharmaceutically acceptable salt thereof; and
c) a container.

### Claim 6 (depends on 1)

A method of inhibiting dipeptidyl peptidase-IV in a mammal comprising administering to said mammal in need of dipeptidyl peptidase inhibition a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 2, 3, 4)

A method of inhibiting dipeptidyl peptidase-IV in a mammal comprising administering to said mammal in need of dipeptidyl peptidase-IV inhibition a therapeutically effective amount of a pharmaceutical composition of any one of claims 2, 3 or 4.

### Claim 8 (depends on 1)

A method of treating a condition mediated by dipeptidyl peptidase-IV inhibition in a mammal comprising administering to said mammal in need of such treatment a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 2, 3, 4)

A method of treating a condition mediated by dipeptidyl peptidase-IV inhibition in a mammal comprising administering to said mammal in need of such treatment a therapeutically effective amount of a pharmaceutical composition of any one of claims 2, 3 or 4.

### Claim 10 (depends on 8)

A method of claim 8 wherein said condition treated is Type 2 diabetes, metabolic syndrome, hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, disease progression in Type 2 diabetes, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome or inflammatory bowel syndrome.

### Claim 11 (depends on 10)

The method of claim 10 wherein the condition treated is Type 1 diabetes.

### Claim 12 (depends on 1)

A prodrug of a compound of claim 1, or a pharmaceutically acceptable salt of said prodrug.
